Home  |  Contact

Cellosaurus 451Lu-MR (CVCL_DG54)

[Text version]
Cell line name 451Lu-MR
Accession CVCL_DG54
Resource Identification Initiative To cite this cell line use: 451Lu-MR (RRID:CVCL_DG54)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:75998; Trametinib (Mekinist; GSK1120212).
Derived from site: Metastatic; Arm, skin; UBERON=UBERON_0002427.
Sequence variations
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61fs*59 (c.179dupC) (p.Gly75fs, c.222dupC); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line).
Disease Cutaneous melanoma (NCIt: C3510)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_6357 (451Lu)
Sex of cell Male
Age at sampling 22Y
Category Cancer cell line
Publications

PubMed=24055054; DOI=10.1016/j.celrep.2013.08.023
Villanueva J., Infante J.R., Krepler C., Reyes-Uribe P., Samanta M., Chen H.-Y., Li B., Swoboda R.K., Wilson M., Vultur A., Fukunaga-Kalabis M., Wubbenhorst B., Chen T.Y., Liu Q., Sproesser K., DeMarini D.J., Gilmer T.M., Martin A.-M., Marmorstein R., Schultz D.C., Speicher D.W., Karakousis G.C., Xu W., Amaravadi R.K., Xu X.-W., Schuchter L.M., Herlyn M., Nathanson K.L.
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.
Cell Rep. 4:1090-1099(2013)

Cross-references
Cell line databases/resources cancercelllines; CVCL_DG54
Encyclopedic resources Wikidata; Q54603182
Gene expression databases GEO; GSM1199179
Polymorphism and mutation databases Progenetix; CVCL_DG54
Entry history
Entry creation13-Jul-2016
Last entry update05-Oct-2023
Version number13